Drug intelligence / Profile preview

TORL-5-700

Development stage: Phase 2
Lead developer: TORL BioTherapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**TORL-5-700** is a preclinical antibody-drug conjugate (ADC) developed by TORL BioTherapeutics for hematologic malignancies. It targets an undisclosed antigen and is part of the company's pipeline of novel ADCs designed to address high unmet needs in oncology, leveraging their platform derived from collaborations with UCLA's Slamon Research Lab. The program reflects TORL's strategy to expand beyond solid tumor ADCs like TORL-1-23 into blood cancers, amid a competitive landscape.[10][8]

Beyond the preview

Go deeper on TORL-5-700.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TORL-5-700.

Explore the full profile